More venting, I don't see anything of substance here...
It's funny to me how everyone criticizes the dilutions, the company wouldn't have had money to get ceplene through the EMEA without the dilutions, it's like some shareholders would prefer 100 more deals with Hurcules than to dilute. I understand the people that have been hurt recently by the falling price of the stock, I am one of those people....but this management got Ceplene approved, that's huge, we could double the shares o/s at this point, and "IF" the partner/commercialization comes through, the stock still has huge potential.
IDIS revenue will not be significant, but it is possible for very few patients to cover their operating expenses.
I'm telling the Board and everyone now, you should not be surprised to see an additional authorization of shares (every pharma needs reserves), and you should probably expect another dilution at some point. Hopefully this will come after a partner is announced/commercialization, or otherwise. The company right now needs to trade over $1 a share for a number of consecutive days to keep their listing - Management owns a ton of shares of this stock, the agency risk right now is heavily tilted in the shareholders failure, management doesn't want to dilute this stock any more than the shareholders.